All In Biotech

Drug Trial Radar · NCT05938036

Study of Safety and Efficacy of ALT-100mAb in Participants With Moderate/Severe ARDS

PUERTA: A P2A Multi-center, Randomized, Double-blind, Placebo-controlled Study Assessing Safety and Efficacy of the eNAMPT Targeting mAb ALT-100 in Moderate/Severe ARDS/VILI Patients

Last checked: Nov 19, 2026Latest source record: Oct 23, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

15

Actual

Start

Dec 1, 2023

Primary completion

May 1, 2027

Study completion Jul 1, 2027

Sponsor

Lead sponsor
Aqualung Therapeutics Corp.Industry
Sponsor type
Industry
First posted
Jul 10, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 100 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

A Phase 2a, multi-center, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of ALT-100mAb in patients with moderate to severe ARDS.

Conditions

  • Acute Respiratory Distress Syndrome (ARDS)

Interventions

  • ALT-100 mAbDrug

    Experimental: Part A : ALT-100 mAB (Dose Escalation) 90 eligible participants will be randomized at a 2:1 ratio to receive a single dose of ALT-100 mAb.

  • ALT-100 (Placebo)Drug

    Normal saline solution via IV solution

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To evaluate the Safety and tolerability of a single intravenously (IV) infused dose of ALT-100 in participants with moderate to severe ARDS: Incidence and severity of treatment-emergent adverse events (TEAEs) from Day 1 to end of study (EOS).Time frame: Up to 60 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Banner University of Arizona

    Tucson, Arizona

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.